Houston, United States
Stellanova Therapeutics, founded in 2019, is a pioneering force in the Biotechnology and Health Care industries. With its headquarters in the United States, this ambitious startup is driven by the mission of "Conquering Cancer".
Stellanova is uniquely positioned due to its innovative cancer therapy development, notably focusing on cancer-associated fibroblasts (CAFs) within the tumor microenvironment. Building on research from Dr. Rosa Hwang's lab at the MD Anderson Cancer Center, the company aims to revolutionize cancer treatment by targeting factors produced by stellate cells, particularly in pancreatic cancer.
Their last recorded investment was a $15.50M Series A funding round on 01 June 2021, led by Sporos Bioventures. Stellanova's approach not only has the potential to attack cancer directly but also enhances the efficacy of existing therapies such as chemotherapy and immunotherapy, offering a compelling value proposition to investors interested in transformative cancer treatments.
